Caprock Group LLC Cuts Stake in West Pharmaceutical Services, Inc. (NYSE:WST)

Caprock Group LLC reduced its stake in West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,047 shares of the medical instruments supplier’s stock after selling 79 shares during the period. Caprock Group LLC’s holdings in West Pharmaceutical Services were worth $369,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Sunbelt Securities Inc. purchased a new stake in shares of West Pharmaceutical Services during the first quarter valued at $25,000. RVW Wealth LLC purchased a new stake in shares of West Pharmaceutical Services during the third quarter valued at $38,000. Planned Solutions Inc. purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at $39,000. International Assets Investment Management LLC purchased a new stake in shares of West Pharmaceutical Services during the third quarter valued at $53,000. Finally, Addison Advisors LLC boosted its position in shares of West Pharmaceutical Services by 37.9% during the third quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 39 shares during the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on WST. KeyCorp increased their price objective on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research report on Tuesday, February 13th. UBS Group lowered their target price on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a report on Friday, February 16th. Jefferies Financial Group raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their target price for the company from $323.00 to $536.00 in a report on Wednesday, February 7th. Finally, StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, February 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $435.20.

Get Our Latest Stock Report on WST

Insider Transactions at West Pharmaceutical Services

In other news, VP Charles Witherspoon sold 2,019 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $358.62, for a total value of $724,053.78. Following the transaction, the vice president now owns 1,979 shares of the company’s stock, valued at $709,708.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Charles Witherspoon sold 2,019 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $358.62, for a total transaction of $724,053.78. Following the sale, the vice president now owns 1,979 shares of the company’s stock, valued at approximately $709,708.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Silji Abraham sold 7,012 shares of West Pharmaceutical Services stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $365.00, for a total value of $2,559,380.00. Following the sale, the senior vice president now directly owns 4,660 shares in the company, valued at approximately $1,700,900. The disclosure for this sale can be found here. Insiders have sold 73,978 shares of company stock valued at $26,653,772 over the last quarter. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Stock Up 0.1 %

NYSE WST opened at $395.94 on Tuesday. The stock’s 50-day moving average price is $377.47 and its 200-day moving average price is $363.47. The company has a quick ratio of 2.24, a current ratio of 2.88 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 52 week low of $310.42 and a 52 week high of $415.73. The company has a market capitalization of $28.99 billion, a P/E ratio of 50.25, a price-to-earnings-growth ratio of 6.75 and a beta of 1.04.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last posted its quarterly earnings data on Thursday, February 15th. The medical instruments supplier reported $1.83 EPS for the quarter, topping the consensus estimate of $1.78 by $0.05. West Pharmaceutical Services had a return on equity of 21.60% and a net margin of 20.12%. The firm had revenue of $732.00 million for the quarter, compared to the consensus estimate of $740.43 million. During the same quarter last year, the company earned $1.77 earnings per share. The business’s revenue for the quarter was up 3.3% compared to the same quarter last year. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 7.63 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Wednesday, April 24th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.20%. The ex-dividend date is Tuesday, April 23rd. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 10.15%.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

See Also

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.